Insider Trading Alert - ICPT, FMNB And TIPT Traded By Insiders

Yesterday, April 6, 2016, 45 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $197.78 to $2,952,262.40.

Highlighted Stocks Traded by Insiders:

Intercept Pharmaceuticals (ICPT) - FREE Research Report

Duncan Barbara Gayle, who is Chief Financial Officer at Intercept Pharmaceuticals, sold 144 shares at $130.76 on April 6, 2016. Following this transaction, the Chief Financial Officer owned 30,948 shares meaning that the stake was reduced by 0.46% with the 144-share transaction.

Pruzanski Mark, who is CEO & President at Intercept Pharmaceuticals, sold 708 shares at $130.76 on April 6, 2016. Following this transaction, the CEO & President owned 548,248 shares meaning that the stake was reduced by 0.13% with the 708-share transaction.

Shapiro David, who is CMO and EVP - Development at Intercept Pharmaceuticals, sold 165 shares at $130.76 on April 6, 2016. Following this transaction, the CMO and EVP - Development owned 48,546 shares meaning that the stake was reduced by 0.34% with the 165-share transaction.

McMinn Rachel, who is Chief Strategy Officer at Intercept Pharmaceuticals, sold 104 shares at $130.76 on April 6, 2016. Following this transaction, the Chief Strategy Officer owned 14,217 shares meaning that the stake was reduced by 0.73% with the 104-share transaction.

Bright Lisa, who is Officer at Intercept Pharmaceuticals, sold 153 shares at $130.76 on April 6, 2016. Following this transaction, the Officer owned 19,106 shares meaning that the stake was reduced by 0.79% with the 153-share transaction.

The shares most recently traded at $163.83, up $33.07, or 20.19% since the insider transaction. Historical insider transactions for Intercept Pharmaceuticals go as follows:

  • 4-Week # shares bought: 800
  • 4-Week # shares sold: 241
  • 12-Week # shares bought: 800
  • 12-Week # shares sold: 369
  • 24-Week # shares bought: 800
  • 24-Week # shares sold: 3,605

The average volume for Intercept Pharmaceuticals has been 784,600 shares per day over the past 30 days. Intercept Pharmaceuticals has a market cap of $3.3 billion and is part of the health care sector and drugs industry. Shares are down 10.58% year-to-date as of the close of trading on Tuesday.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Currently, there are 5 analysts who rate Intercept Pharmaceuticals a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ICPT - FREE

TheStreet Quant Ratings rates Intercept Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Intercept Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Farmers National Banc (FMNB) - FREE Research Report

VanSickle James R, who is SVP, Chief Risk Officer at Farmers National Banc, bought 67 shares at $8.99 on April 6, 2016. Following this transaction, the SVP, Chief Risk Officer owned 60,648 shares meaning that the stake was boosted by 0.11% with the 67-share transaction.

Paull David Z, who is Director at Farmers National Banc, bought 28 shares at $8.99 on April 6, 2016. Following this transaction, the Director owned 34,211 shares meaning that the stake was boosted by 0.08% with the 28-share transaction.

Sabat Joseph W, who is VP/Controller at Farmers National Banc, bought 55 shares at $8.99 on April 6, 2016. Following this transaction, the VP/Controller owned 4,287 shares meaning that the stake was boosted by 1.3% with the 55-share transaction.

Wallace Amber B, who is Sr VP/Chief Retail/Marketing at Farmers National Banc, bought 22 shares at $8.99 on April 6, 2016. Following this transaction, the Sr VP/Chief Retail/Marketing owned 17,575 shares meaning that the stake was boosted by 0.13% with the 22-share transaction.

Shaffer Timothy F, who is SVP, Regional President at Farmers National Banc, bought 22 shares at $8.99 on April 6, 2016. Following this transaction, the SVP, Regional President owned 15,002 shares meaning that the stake was boosted by 0.15% with the 22-share transaction.

Historical insider transactions for Farmers National Banc go as follows:

  • 4-Week # shares bought: 1,465
  • 12-Week # shares bought: 4,435
  • 24-Week # shares bought: 30,266

The average volume for Farmers National Banc has been 25,100 shares per day over the past 30 days. Farmers National Banc has a market cap of $242.4 million and is part of the financial sector and banking industry. Shares are up 4.65% year-to-date as of the close of trading on Wednesday.

Farmers National Banc Corp. operates as a holding company for The Farmers National Bank of Canfield that provides commercial and retail banking products and services in Ohio. The stock currently has a dividend yield of 1.78%. The company has a P/E ratio of 25.0. Currently, there are 2 analysts who rate Farmers National Banc a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FMNB - FREE

TheStreet Quant Ratings rates Farmers National Banc as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Farmers National Banc Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Tiptree Financial (TIPT) - FREE Research Report

Barnes Michael Gene, who is Executive Chairman at Tiptree Financial, bought 5,000 shares at $5.71 on April 6, 2016. Following this transaction, the Executive Chairman owned 3.5 million shares meaning that the stake was boosted by 0.14% with the 5,000-share transaction.

The shares most recently traded at $5.68, down $0.03, or 0.55% since the insider transaction. Historical insider transactions for Tiptree Financial go as follows:

  • 4-Week # shares bought: 36,490
  • 4-Week # shares sold: 13,731
  • 12-Week # shares bought: 123,293
  • 12-Week # shares sold: 135,332
  • 24-Week # shares bought: 256,667
  • 24-Week # shares sold: 135,332

The average volume for Tiptree Financial has been 86,000 shares per day over the past 30 days. Tiptree Financial has a market cap of $241.3 million and is part of the financial sector and insurance industry. Shares are down 10.1% year-to-date as of the close of trading on Tuesday.

TipTree Financial Inc., formerly Care Investment Trust, operates as a real estate investment trust (REIT). It engages in originating and acquiring healthcare-related real estate and commercial mortgage debt. The stock currently has a dividend yield of 1.78%.

Exclusive Offer: Get the latest Stock Analysis on TIPT - FREE

TheStreet Quant Ratings rates Tiptree Financial as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself. Get the full Tiptree Financial Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Global Stocks Hit by Asia Tech Weakness, Oil Price Rally; U.S. Futures Slip

Global Stocks Hit by Asia Tech Weakness, Oil Price Rally; U.S. Futures Slip

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs